Business Description
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 62.76 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -43.7 | |||||
3-Year EPS without NRI Growth Rate | -40.9 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
3-Year Book Growth Rate | 47.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.6 | |||||
9-Day RSI | 26.51 | |||||
14-Day RSI | 24.5 | |||||
6-1 Month Momentum % | -13.82 | |||||
12-1 Month Momentum % | 360.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.6 | |||||
Quick Ratio | 9.6 | |||||
Cash Ratio | 9.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.9 | |||||
Shareholder Yield % | -98.42 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -29.71 | |||||
ROA % | -25.24 | |||||
ROIC % | -67.99 | |||||
ROC (Joel Greenblatt) % | -266.36 | |||||
ROCE % | -20.92 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.89 | |||||
Price-to-Tangible-Book | 1.14 | |||||
EV-to-EBIT | -0.34 | |||||
EV-to-Forward-EBIT | -0.26 | |||||
EV-to-EBITDA | -0.36 | |||||
EV-to-Forward-EBITDA | -0.29 | |||||
EV-to-Forward-Revenue | 19.15 | |||||
EV-to-FCF | -0.75 | |||||
Price-to-Projected-FCF | 2.61 | |||||
Price-to-Net-Current-Asset-Value | 1.4 | |||||
Price-to-Net-Cash | 1.41 | |||||
Earnings Yield (Greenblatt) % | -294.48 | |||||
FCF Yield % | -14.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.338 | ||
Beta | 1.98 | ||
Volatility % | 135.46 | ||
14-Day RSI | 24.5 | ||
14-Day ATR (€) | 0.55822 | ||
20-Day SMA (€) | 7.348 | ||
12-1 Month Momentum % | 360.87 | ||
52-Week Range (€) | 2.14 - 17.2 | ||
Shares Outstanding (Mil) | 67.59 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Perspective Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(STU:AAJ0)'s stock price today?
When is next earnings date of Perspective Therapeutics Inc(STU:AAJ0)?
Does Perspective Therapeutics Inc(STU:AAJ0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |